Cite
HARVARD Citation
Brahmer, J. et al. (2023). Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227. Journal of clinical oncology. 41 (6), pp. 1200-1212. [Online].